tradingkey.logo
๎™
๎™ผ
tradingkey.logo
๎™

Regentis Biomaterials Ord Shs

RGNT
3.010USD
-0.030-0.99%
์‹œ์žฅ ์šด์˜ ์‹œ๊ฐ„ย ๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
0.00์‹œ๊ฐ€์ด์•ก
--P/E TTM
๎™

Regentis Biomaterials Ord Shs

3.010
-0.030-0.99%

์ž์„ธํ•œ ๋‚ด์šฉ์€ Regentis Biomaterials Ord Shs ํšŒ์‚ฌ

Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.

Regentis Biomaterials Ord Shs ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ RGNT
ํšŒ์‚ฌ ์ด๋ฆ„Regentis Biomaterials Ltd
์ƒ์žฅ์ผDec 04, 2025
CEOHazum (Eli)
์ง์› ์ˆ˜- -
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒ- -
์ฃผ์†Œ60, Medinat Hyahudim
๋„์‹œHERZLIYA
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX โ€“ NASDAQ Basic Amex
๊ตญ๊ฐ€Israel
์šฐํŽธ ๋ฒˆํ˜ธ4676652
์ „ํ™”97246265502
์›น์‚ฌ์ดํŠธhttps://www.regentis.co.il/
์ข…๋ชฉ ์ฝ”๋“œ RGNT
์ƒ์žฅ์ผDec 04, 2025
CEOHazum (Eli)

Regentis Biomaterials Ord Shs์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Dr. Ehud Geller, Ph.D.
Dr. Ehud Geller, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Eli Hazum
Dr. Eli Hazum
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Arie Gordashnikov, CPA
Mr. Arie Gordashnikov, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jeff Dykan, CPA
Mr. Jeff Dykan, CPA
Director
Director
--
--
Dr. Susan Alpert, M.D., Ph.D.
Dr. Susan Alpert, M.D., Ph.D.
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Catherine C. (Keith) Valentine
Mr. Catherine C. (Keith) Valentine
Independent Director
Independent Director
--
--
Mr. Efraim Cohen-Arazi
Mr. Efraim Cohen-Arazi
Independent Director Nominee
Independent Director Nominee
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Dr. Ehud Geller, Ph.D.
Dr. Ehud Geller, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Eli Hazum
Dr. Eli Hazum
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Arie Gordashnikov, CPA
Mr. Arie Gordashnikov, CPA
Chief Financial Officer
Chief Financial Officer
--
--

์ˆ˜์ต ๋ถ„์„

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Mar 16
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Mar 16
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
HaisThera Scientific Fund I, L.P
11.90%
Vitalife Life Sciences Venture Capital
7.74%
Ocorian Fund Management S.a.r.l
5.72%
Medica Venture Partners
5.05%
DSM Venturing B.V.
5.04%
๊ธฐํƒ€
64.54%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
HaisThera Scientific Fund I, L.P
11.90%
Vitalife Life Sciences Venture Capital
7.74%
Ocorian Fund Management S.a.r.l
5.72%
Medica Venture Partners
5.05%
DSM Venturing B.V.
5.04%
๊ธฐํƒ€
64.54%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Corporation
17.63%
Venture Capital
12.78%
Hedge Fund
5.43%
Private Equity
5.05%
Individual Investor
1.42%
๊ธฐํƒ€
57.69%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
๋ฐ์ดํ„ฐ ์—†์Œ
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
์ด๋ฆ„
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
๋ฐฐ๋‹น๋ฝ์ผ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
๋‚ ์งœ
๋ฐฐ๋‹น๋ฝ์ผ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
KeyAI
๎™